Business
Marizyme, Inc., Agrees to Distribute Somahlution's DuraGraft Products in South America and Mexico
Marizyme, Inc., Agrees to Distribute Somahlution's DuraGraft Products in South America and Mexico.
About this update from Marizyme, Inc.
[{"type":"text","content":"\n\n\n\nMarizyme, Inc., Agrees to Distribute Somahlution's DuraGraft Products in South America and Mexico\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMarizyme, Inc., Agrees to Distribute Somahlution's DuraGraft Products in South America and Mexico\nPR Newswire\nDAVENPORT, Fla., Oct. 11, 2019\n\n\n\nDAVENPORT, Fla., Oct. 11, 2019 /PRNewswire/ -- Marizyme, Inc. (\"Marizyme\" or the \"Company\"), a publicly traded (OTC:MRZM) company focused on acquiring late-stage drug assets to develop for use in the acute care space, announced today that they have agreed to exclusively distribute Somahlution's DuraGraft® products in Mexico and South America. The agreement also gives Marizyme the exclusive right to manufacture those products in Chile where it has relationships to create manufacturing and distribution channels and extend them into the rest of South America.\nMr. Nicholas DeVito, Marizyme, CEO, commented, \"We are excited to be working with Somahlution. Using our relationships in Chile we expect to finalize product approval throughout South America and begin distribution in 2020.\"\nDuraGraft® is a one-time intraoperative vascular graft treatment used during vascular surgery to reduce the incidence of complications associated with graft failure and improving clinical outcomes by maintaining normal graft function. DuraGraft mitigates Ischemic Injury to maintain endothelial function and structure during the storage interval.\nMr. Satish Chandran, Somahlution, CEO, added, \"We believe Marizyme will be an excellent partner for us. Our patented products have undergone extensive clinical trials in Europe and Canada and been approved for use throughout the EU and several other countries around the world.\"\nCoronary Artery Bypass Grafting Surgery alone in the South American and Mexican markets represent a patient population well in excess of 300,000 applicable cases per year once approved for sale.\nDr. Hugo Morales Ballejo, MD, FACC believes, \"Coronary artery bypass grafting (CABG) is one of the most critical operations that needs very important care in each step. O...